Kodiak Sciences Inc (KOD)
Kodiak Sciences is a clinical stage biopharmaceutical company focused on researching, developing and commercializing therapeutics to treat high prevalence retinal diseases. Co.'s Antibody Biopolymer Conjugate Platform (ABC Platform) uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies. Co.'s main product candidate, tarcocimab, is an anti-vascular endothelial growth factor antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including diabetic eye diseases, and wet age-related macular degeneration. Co. has utlized its ABC Platform to build a pipeline of product candidates in various stages of development.
KOD SEC Filing Email Alerts Service
Company Name: |
Kodiak Sciences Inc |
Website: |
www.kodiak.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding KOD: |
14 |
Total Market Value Held by ETFs: |
$16.88M |
Total Market Capitalization: |
$373.00M |
% of Market Cap. Held by ETFs: |
4.53% |
|
|
March 28, 2024 6:54 PM Eastern
Sell (1.00 out of 4)
0th percentile
|
|